The TIMP-1 protein levels in both tissues and blood have been repeatedly associated with a poor prognosis in lung cancers, but its role in this cancer process was, to date, unknown. Now, a study led by Jordi Alcaraz, lecturer at the Faculty of Medicine and Health Sciences of the University of Barcelona – UB – and researcher at the Institute for Bioengineering of Catalonia (IBEC), has determined that this protein is not only a promising biomarker, but it is also involved in the progression of lung adenocarcinoma, writes the UB in a press release.
“In recent decades, cancer research has been aimed at having more specific treatments for each type of tumour and patient, improving the patients’ prognosis. In this line, this study is relevant because it identifies a therapeutic target for those patients with adenocarcinoma subtype non-small cell lung cancer, the most common lung cancer”, notes Paula Duch, UB researcher and first author of the article.
A unique collection of patient-derived fibroblasts in Spain
TIMP-1 is a protein unusually secreted by fibroblasts, a type of non-malignant cell that accompanies cancer cells and is the main component of what is called the tumour microenvironment. To understand the role of TIMP-1 in this process, the researchers used a unique collection of fibroblasts derived from lung cancer patients at the Hospital Clínic in Spain. Specifically, they performed cell culture assays in vitro and in vivo on non-small cell lung cancer, which accounts for up to 85 percent of lung cancers and is subdivided into two subtypes: adenocarcinoma and squamous cell carcinoma.
Protumour interaction with the CD63 receptor
The results first showed that elevated levels of TIMP-1 in lung cancer are due to fibroblasts secreting “pathological levels” of this protein. Next, they found that TIMP-1 from fibroblasts causes increased tumour proliferation and invasion when interacting with the CD63 receptor on cancer cells. And finally, they found that “this tumour axis formed by the interaction between TIMP-1 and CD63 occurs only in the adenocarcinoma subtype and not in squamous cell carcinoma”, says Jordi Alcaraz, also a researcher at CIBERES.
New therapeutic strategy
These results may facilitate the development of new therapies directed against this pathological interaction. “Knowing that patients with adenocarcinoma have hyperactive fibroblasts that secrete TIMP-1 excessively allows us to consider the use of therapies that prevent its secretion,” explains Paula Duch.
In this sense, the study, in addition to showing that fibroblasts play a very important role in tumour progression, also opens up a way to “attack this tumour axis”: the so-called antifibrotic drugs, developed to inhibit the pathological functions of these cells. “The idea is to examine whether antifibrotic drugs are capable of inhibiting the abnormal secretion of TIMP-1 and whether this reduces the progression of adenocarcinoma tumours”, says the researcher. “In the long term —she adds— if this approach works, the use of these antifibrotic drugs in combination with anti-cancer therapies that attack other aspects of the tumour, such as immunotherapy, could be considered”.
Selected for you!
Innovation Origins is the European platform for innovation news. In addition to the many reports from our own editors in 15 European countries, we select the most important press releases from reliable sources. This way you can stay up to date on what is happening in the world of innovation. Are you or do you know an organization that should not be missing from our list of selected sources? Then report to our editorial team.
Related Posts
